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Anterior Myocardial Infarction
Primum non Nocere, or First Do No Harm*Michael C. McDaniel, MDL eft ventricular (LV) mural thrombus is a com-mon complication of anterior myocardial in-farctions (MIs). Although this incidence has
signiﬁcantly decreased with reperfusion therapies,
contemporary studies still note LV thrombus in 3%
to 15% of anterior MIs treated with percutaneous cor-
onary revascularization (1,2). Furthermore, pooled
analyses suggest a more than 5-fold increased risk
for systemic embolism with LV thrombus after ante-
rior MI, and anticoagulation therapy is associated
with a signiﬁcant decrease in this embolic risk (3).
As such, the 2013 American College of Cardiology
Foundation/American Heart Association ST-segment
elevation myocardial infarction (STEMI) guidelines
recommend anticoagulation for patients with acute
MI and asymptomatic LV mural thrombus (Class IIa,
Level of Evidence [LOE]: C) (4). Given the increased
risk of bleeding with anticoagulation and dual anti-
platelet therapy, these guidelines suggest lower in-
ternational normalized ratio goals (2.0 to 2.5) in this
clinical setting (Class IIb, LOE: C).
Anticoagulation after anterior MI with risk factors
for mural thrombus formation is much more contro-
versial, as the risk of clinically-signiﬁcant thrombo-
embolism in contemporary practice is not well
understood. Currently, the 2013 American College of
Cardiology Foundation/American Heart Association
STEMI guidelines state that anticoagulation therapy
may be considered for patients with STEMI and
anterior apical akinesis or dyskinesis (Class IIb,
LOE: C) (4). However, this recommendation is based*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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beneﬁts of anticoagulation outweigh the known
bleeding risks in current practice. Triple therapy
(aspirin, clopidogrel, and warfarin) after percuta-
neous coronary intervention (PCI) is associated with
a 2- to 5-fold greater risk of major bleeding com-
pared with dual antiplatelet therapy (1,5,6).
There are good reasons to consider anticoagulation
after anterior MI. Larger infarctions, anterior loca-
tions, and lower ejection fractions are associated with
higher rates of mural thrombus formation (2,7,8). In
addition, a meta-analysis of 307 patients from 4
studies conducted prior to the use of thrombolytics
suggests that anticoagulation decreases the incidence
of LV thrombus formation by 68% (3). Furthermore,
the risk of ischemic stroke is higher following acute
MI, with an incidence of about 1.5% to 3.6% (3,9).
This risk is greatest in the ﬁrst month and is also
more common in patients with anterior infarctions
and lower ejection fractions (9–11). Importantly,
anticoagulation has been shown to reduce the
incidence of stroke and mortality after acute MI in
randomized studies from the pre-thrombolytic era
(12,13).
However, not all studies ﬁnd a link among anterior
MI, LV thrombus, and embolic events. In the throm-
bolytic era, the low molecular weight heparin dalte-
parin reduced LV thrombus formation by 37% in 517
randomized patients after anterior acute MI. Howev-
er, this therapy had no impact on early thromboem-
bolic events (14). Similar ﬁndings were echoed in a
larger observational study of 2,949 patients, in which
anticoagulation failed to reduce the incidence of
stroke after anterior MI (10).
The study by LeMay et al. (15) published in this issue
of JACC: Cardiovascular Interventions builds on these
prior observations and reports the outcomes of anti-
coagulation in 460 STEMI patients with apical
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164dysfunction after PCI. This study is important, as it is
the largest study from the PCI era to evaluate anti-
coagulation in this population, and the authors should
be congratulated for investigating a controversial topic
for which the best practice is unknown. In this study,
patients requiring anticoagulation for LV thrombus,
atrial ﬁbrillation, valvular heart disease, or venousSEE PAGE 155thromboembolism were excluded. The authors found
that anticoagulation was actually associated with an
increased incidence of stroke (3.1% vs. 0.3%, p ¼ 0.02),
major bleeding (8.5% vs. 1.8%, p < 0.0001), mortality
(5.4% vs. 1.5%, p ¼ 0.04), length of stay, and read-
missions. Furthermore, after propensity matching,
anticoagulation was still associated with a 4-fold
greater incidence of net adverse cardiac events. In
multivariable analysis, the odds of net adverse cardiac
events remained higher in patients treated with anti-
coagulation. These ﬁndings certainly question the
routine use of triple therapy in this population.
There are limitations to the current analysis. The
study was not randomized, and it is possible that the
outcomes of the study were related to differences
between groups, even after propensity matching. In
addition, the current analysis may not represent
current practice, as several recent studies suggest
that aspirin can often be omitted when anticoa-
gulation is warranted after PCI. In the 573-patient
randomized WOEST (What is the Optimal antiplatElet
and anticoagulant therapy in patients with oral anti-
coagulation and coronary StenTing) trial, omission
of aspirin decreased major bleeding complications(44.4% vs. 19.4%, p < 0.0001) without any increase in
ischemic events (16). These ﬁndings were echoed in a
larger real-world registry of 12,165 patients undergo-
ing PCI requiring anticoagulation (17). Whether the
omission of aspirin would have inﬂuenced the results
of the current trial is unknown.
In conclusion, the current study by Le May et al.
(15) warns against the routine use of anticoagulation
in patients with anterior MI with apical dysfunction
without evidence of mural thrombus. Given the
bleeding risks, triple therapy should probably be
avoided in these patients. Whether the combination
of clopidogrel and warfarin without aspirin is more
effective than dual antiplatelet therapy in these pa-
tients is unknown, and randomized studies should
be considered to investigate this strategy. Until such
a trial is conducted, if anticoagulation is used after
anterior MI, clinicians should probably consider
omitting aspirin, adding proton pump inhibitors,
targeting lower international normalized ratio ranges,
shortening the anticoagulation course (3 months),
and using radial access. Furthermore, it should be
noted that the safety of the novel anticoagulant and
antiplatelet therapies in this setting has not been
tested. Ultimately, better risk assessment tools are
needed to guide therapeutic decisions balancing the
risk of LV thrombus formation and thromboembo-
lism with the risk of bleeding.
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